Literature DB >> 28710050

Transforaminal Endoscopic Lumbar Discectomy for Lumbar Disc Herniation Causing Bilateral Symptoms.

Chunpeng Ren1, Yin Li1, Rujie Qin2, Penghao Sun1, Peng Wang1.   

Abstract

BACKGROUND: Transforaminal endoscopic lumbar discectomy (TELD), a minimally invasive spinal technique, has advantages over open discectomy. Unilateral TELD for disc herniation causing bilateral symptoms is challenging. In this study, we describe a percutaneous endoscopic herniotomy technique by using a unilateral approach for lumbar disc herniation with bilateral obvious symptoms.
METHODS: From June 2014 to October 2015, 26 patients who had back as well as bilateral leg pain and/or weakness due to lumbar disc herniation were treated by TELD with a unilateral approach. Clinical outcomes were evaluated via a visual analogue scale (VAS; 0-10), and functional status was assessed with the Oswestry Disability Index (0-100%) postoperatively and 3 and 12 months postoperatively. Surgical satisfaction rate was assessed during the final follow-up.
RESULTS: The mean VAS for leg pain on the operative side improved from preoperative 8.39 ± 1.84 to 2.18 ± 1.26 postoperatively, 1.96 ± 0.83 at 3 months postoperatively, and 2.05 ± 1.42 at 1 year postoperatively (P < 0.01). The mean VAS for leg pain on the contralateral was 7.12 ± 1.74 and improved to 1.57 ± 1.66 postoperatively, 1.22 ± 1.58 at 3 months postoperatively, and 1.15 ± 1.35 at 1 year postoperatively (P < 0.01). The mean preoperative Oswestry Disability was 83.63 ± 8.49, with 23.58 ± 7.24 at 1 week postoperatively, 19.81 ± 11.26 at 3 months postoperatively, and 17.54 ± 13.40 at 12 months postoperatively (P < 0.01). Good or excellent global results were obtained in 96.2% of patients.
CONCLUSIONS: TELD can be effective for lumbar disc herniation causing bilateral symptoms, through one working channel.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Leg pain; Lumbar disc herniation; Percutaneous endoscopic lumbar discectomy; Transforaminal endoscopic lumbar discectomy

Mesh:

Year:  2017        PMID: 28710050     DOI: 10.1016/j.wneu.2017.06.191

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  6 in total

1.  Is exclusion of leukocytes from platelet-rich plasma (PRP) a better choice for early intervertebral disc regeneration?

Authors:  Shan-Zheng Wang; Wei-Min Fan; Jun Jia; Liang-Yu Ma; Jia-Bin Yu; Chen Wang
Journal:  Stem Cell Res Ther       Date:  2018-07-18       Impact factor: 6.832

2.  Application of a modified optical fiber in targeted percutaneous laser disc decompression of lumbar disc herniation: A retrospective study.

Authors:  Chao Meng; Yujun Li; Shijie Wang; Junmin Yu; Dewei Kou; Chuansheng Liu
Journal:  Exp Ther Med       Date:  2019-09-06       Impact factor: 2.447

3.  Percutaneous endoscopic lumbar discectomy for lumbar disc herniation as day surgery - short-term clinical results of 235 consecutive cases.

Authors:  Jian Cao; Wenzhou Huang; Tianlong Wu; JingYu Jia; Xigao Cheng
Journal:  Medicine (Baltimore)       Date:  2019-12       Impact factor: 1.889

4.  The biomechanical effect of the relevant segments after facet-disectomy in different diameters under posterior lumbar percutaneous endoscopes: a three-dimensional finite element analysis.

Authors:  Yin Shi; Yi-Zhou Xie; Qun Zhou; Yang Yu; Xiao-Hong Fan
Journal:  J Orthop Surg Res       Date:  2021-10-14       Impact factor: 2.359

5.  A Comparison Between Retaining and Resecting the Posterior Longitudinal Ligament in Percutaneous Endoscopic Transforaminal Discectomy for Disc Herniation: A Retrospective Cohort Study.

Authors:  Wenhao Hu; Fanqi Hu; Chao Liu; Weibo Liu; Yi Jiang; Jing Li; Yan Wang; Teng Li; Li Li; Xuesong Zhang
Journal:  Orthop Surg       Date:  2022-04-21       Impact factor: 2.279

6.  Transforaminal Endoscopic Discectomy and Foraminoplasty for Treating Central Lumbar Stenosis.

Authors:  Bei-Xi Bao; Jian-Wei Zhou; Pan-Feng Yu; Cheng Chi; Hua Qiang; Hui Yan
Journal:  Orthop Surg       Date:  2019-11-12       Impact factor: 2.071

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.